317 related articles for article (PubMed ID: 21765211)
21. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
22. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.
Liu X; He S; Wu H; Xie H; Zhang T; Deng Z
Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288
[TBL] [Abstract][Full Text] [Related]
23. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
Ostrand-Rosenberg S; Clements VK; Terabe M; Park JM; Berzofsky JA; Dissanayake SK
J Immunol; 2002 Nov; 169(10):5796-804. PubMed ID: 12421960
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
[TBL] [Abstract][Full Text] [Related]
25. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma.
Tran L; Allen CT; Xiao R; Moore E; Davis R; Park SJ; Spielbauer K; Van Waes C; Schmitt NC
Cancer Immunol Res; 2017 Dec; 5(12):1141-1151. PubMed ID: 29097421
[TBL] [Abstract][Full Text] [Related]
27. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues.
Tel J; Hato SV; Torensma R; Buschow SI; Figdor CG; Lesterhuis WJ; de Vries IJ
Cancer Immunol Immunother; 2012 Jul; 61(7):1101-11. PubMed ID: 22193989
[TBL] [Abstract][Full Text] [Related]
28. Nitric oxide contributes to host resistance against experimental Taenia crassiceps cysticercosis.
Alonso-Trujillo J; Rivera-Montoya I; Rodríguez-Sosa M; Terrazas LI
Parasitol Res; 2007 May; 100(6):1341-50. PubMed ID: 17206501
[TBL] [Abstract][Full Text] [Related]
29. Signal transducer and activation of transcription 6 (STAT6) regulates T helper type 1 (Th1) and Th17 nephritogenic immunity in experimental crescentic glomerulonephritis.
Summers SA; Phoon RK; Odobasic D; Dewage L; Kitching AR; Holdsworth SR
Clin Exp Immunol; 2011 Nov; 166(2):227-34. PubMed ID: 21985369
[TBL] [Abstract][Full Text] [Related]
30. Prostaglandin I2 Suppresses Proinflammatory Chemokine Expression, CD4 T Cell Activation, and STAT6-Independent Allergic Lung Inflammation.
Zhou W; Zhang J; Goleniewska K; Dulek DE; Toki S; Newcomb DC; Cephus JY; Collins RD; Wu P; Boothby MR; Peebles RS
J Immunol; 2016 Sep; 197(5):1577-86. PubMed ID: 27456482
[TBL] [Abstract][Full Text] [Related]
31. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells.
Chen Z; Moyana T; Saxena A; Warrington R; Jia Z; Xiang J
Int J Cancer; 2001 Aug; 93(4):539-48. PubMed ID: 11477558
[TBL] [Abstract][Full Text] [Related]
32. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity.
Micheau O; Solary E; Hammann A; Martin F; Dimanche-Boitrel MT
J Natl Cancer Inst; 1997 Jun; 89(11):783-9. PubMed ID: 9182976
[TBL] [Abstract][Full Text] [Related]
33. STAT6 inhibitory peptide reduces dendritic cell migration to the lymph nodes to control Th2 adaptive immunity in the mouse lung.
Lee S; Shan J; Aldossary H; Gaudreault V; Bazett M; Fixman ED
Eur J Immunol; 2019 Jan; 49(1):157-169. PubMed ID: 30427538
[TBL] [Abstract][Full Text] [Related]
34. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3.
Cortes JR; Perez-G M; Rivas MD; Zamorano J
J Immunol; 2007 Sep; 179(6):3881-7. PubMed ID: 17785825
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
[TBL] [Abstract][Full Text] [Related]
36. Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells.
Jensen SM; Meijer SL; Kurt RA; Urba WJ; Hu HM; Fox BA
J Immunol; 2003 Feb; 170(4):2014-21. PubMed ID: 12574371
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin.
Bakalova AG; Buyukliev RT; Nikolova RP; Shivachev BL; Mihaylova RA; Konstantinov SM
Anticancer Agents Med Chem; 2019; 19(10):1243-1252. PubMed ID: 30767754
[TBL] [Abstract][Full Text] [Related]
38. Sensitization of cisplatin resistant bladder tumor by combination of cisplatin treatment and co-culture of dendritic cells with apoptotic bladder cancer cells.
Zhang Q; Chen Z
Cell Mol Biol (Noisy-le-grand); 2018 Jul; 64(10):102-107. PubMed ID: 30084800
[TBL] [Abstract][Full Text] [Related]
39. Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1).
Wei M; Liu B; Gu Q; Su L; Yu Y; Zhu Z
Cell Oncol (Dordr); 2013 Feb; 36(1):79-93. PubMed ID: 23184467
[TBL] [Abstract][Full Text] [Related]
40. Latency-associated protein Acr1 impairs dendritic cell maturation and functionality: a possible mechanism of immune evasion by Mycobacterium tuberculosis.
Siddiqui KF; Amir M; Gurram RK; Khan N; Arora A; Rajagopal K; Agrewala JN
J Infect Dis; 2014 May; 209(9):1436-45. PubMed ID: 24218502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
